

August 2025 Content Release Notes

August 28, 2025

Contents

Clinical Profile Documentation	2
Additions.....	2
Lab Analytes & Panels	2
Additions and Updates	2
Medications.....	5
Additions.....	5
Updates.....	6
Regimen Library.....	10
Additions.....	10
Updates.....	11
Renames	12
Billing & HCPCS Codes	12
Updates.....	12

Clinical Profile Documentation

Additions

The **Problems > Add Details** area is updated with applicable documentation points for the following diagnoses:

- **Curbside Connect with Dr. Truong or Dr. Sosman** for Melanoma patients is now available for scheduling for **Melanoma, Skin**.

Lab Analytes & Panels

Additions and Updates

The **August 2025 lab release** includes a comprehensive set of diagnostic tests and panels spanning immunology, hematology, toxicology, and genetic analysis. Below is a list of what will be available this month:

- % CD 3 Pos. Lymph, %
- % CD3+CD25+ lymphs, %
- % NK (CD56/16), %
- 6-acetylmorphine, urine (cutoff 10 ng/mL)
- Ab NK (CD56/16), /uL
- Abs.CD3+CD25+ lymphs, /uL
- Absolute CD 3, /uL
- Aldosterone LCMS, serum panel
- Anticardiolipin Ab, IgM, quantitative panel
- Anti-CCP antibodies, IgG and IgA, ELISA panel
- Anti-centromere Ab by EIA panel
- Anti-Jo-1 panel
- Anti-mitochondrial Ab by IFA panel
- Artera AI biomarker test
- Azathioprine panel
- Baso (absolute), x10E3/uL
- Basos, %
- Chromosome analysis colonies counted
- Chromosome analysis fetus info
- Chromosome analysis sub cultures

- Clobazam panel (serum/blood)
- Clobazam, serum, ng/mL
- Complement C1q, quantitative panel
- Coxsackie A IgG antibody panel
- Decipher GC test
- Desmethyloclobazam, serum, ng/mL
- Dihydropyrimidinase (DHAP) deficiency additional information
- Dihydropyrimidinase (DHAP) deficiency interpretation
- Dihydropyrimidinase (DHAP) deficiency panel
- Dihydropyrimidinase (DHAP) deficiency result
- Dihydropyrimidinase (DHAP) deficiency reviewer
- Eos
- Eos (absolute), x10E3/uL
- Hematocrit
- Hematology comments
- Hemoglobin, g/dL
- Hemolytic anemia evaluation panel
- Herpes simplex virus type 1 (HSV-1), type specific antibodies, IgG panel
- Herpes simplex virus type 2 (HSV-2), type-specific antibodies, IgG panel
- HIV-1/HIV-2 qualitative RNA panel
- Immature cells
- Immature grans (Abs), x10E3/uL
- Immature granulocytes, %
- Immunofixation IgD panel
- Invitae BRCA1 panel
- Invitae red blood cell membrane disorders and enzymopathies panel
- Lymphs (absolute), x10E3/uL
- Lymphs, %
- MCH, pg
- MCHC, g/dL
- MCV, fL
- Molecular oncology body site
- Molecular oncology client specimen id
- Molecular oncology comments
- Molecular oncology disclaimer
- Molecular oncology electronically signed by
- Molecular oncology indication

- Molecular oncology interpretation
- Molecular oncology method
- Molecular oncology panel
- Molecular oncology pdf
- Molecular oncology references
- Molecular oncology referring physician
- Molecular oncology referring physician phone
- Molecular oncology reported by
- Molecular oncology results
- Molecular oncology specimen(s) received
- Molecular oncology testing performed
- Molecular oncology treating physician
- Molecular oncology treating physician phone
- Monocytes
- Monocytes(absolute), x10E3/uL
- Multiple myeloma MRD panel
- Mumps antibodies, IgG panel
- NeoGenomics report
- NeoTYPE DNA & RNA - brain (plus MGMT gene promoter methylation analysis) panel
- NeoTYPE DNA & RNA - lung (plus PD-L1) panel
- NeoTYPE DNA & RNA - lung panel
- Neutrophils
- Neutrophils (absolute), x10E3/uL
- NK and activated T cells/IL2r panel
- NRBC, %
- Panel A spot count corrected for neg control
- Panel B spot count corrected for neg control
- Parvovirus B19, human, IgG/IgM panel
- Platelets, x10E3/uL
- Prolaris GC test
- RBC, x10E3/uL
- RDW, %
- RPR with reflex to RPR titer and treponemal antibodies panel
- SM antibody interpretation
- T Pallidum Ab with reflex to RPR and RPR titer, reverse screening panel
- Tempus xT normal match, xF/xF+, xM tissue-free kit panel
- Tetanus/diphtheria antibody panel

- Thrombin–antithrombin complex panel
- TRBC1/T cell lymphoma panel, LGL
- Tropheryma DNA PCR, QL (whipple disease)
- Tropheryma DNA source
- Urinalysis dipstick
- Urinalysis with microscopic, with reflex to culture
- Urinalysis, dipstick w/ reflex to microscopy panel
- WBC, x10E3/uL

Medications

Additions

- AAA601 (Lutetium Lu-177 Dotatate) invest IV
- Apple Cider Vinegar Supplement Oral
- AZD8205 invest IV
- BMS-986504 invest Oral
- Coconut Oil Supplement Oral
- Collagen 1500 Plus C Supplement Oral
- Coromega Supplement Oral
- D-Mannose Supplement Oral
- Firmonertinib invest Oral
- Glucosamine-Chondroit-Vit C-Maganese Supplement Oral
- Green Tea Leaf Extract Supplement Oral
- KB707 invest Intratumoral
- Lutathera invest (AAA601 (Lutetium Lu-177 Dotatate) invest IV)
- MK-1084 invest Oral
- MK-4280A (Favezelimab–Pembrolizumab 800 mg–200 mg) invest IV
Note: The Dose field doesn't support special characters, so '800-200' isn't allowed. Units mg and mL were added instead.
- Pasritamig (JNJ-78278343) invest IV
- Pumpkin Seed Extract Supplement Oral
- Puxitatug Samrotecan invest (AZD8205 invest IV)
- Slippery Elm Bark Supplement Oral
- Syringe with needle 1 mL 25 gauge x 5/8"

Updates

Medications	Updates
AB521 invest Oral	<p>New Alias/Synonym available:</p> <ul style="list-style-type: none"> • Casdatifan invest <p>New Form available:</p> <ul style="list-style-type: none"> • 25 mg tablet <p>New default SIG available:</p> <ul style="list-style-type: none"> • 0 tablets or capsules orally daily <p>New Quick SIG Pick available:</p> <ul style="list-style-type: none"> • 25 mg orally daily • 50 mg orally daily • 100 mg orally daily
ABBV-399 invest IV	<p>Update Form from 100 mg solution to:</p> <ul style="list-style-type: none"> • 100 mg recon soln <p>Remove Instructions:</p> <ul style="list-style-type: none"> • Administer over approximately 30 minutes once every 21 days (Q21D). ABBV-399 must be refrigerated at 2 to 8 degrees C/36 to 46 degree Fahrenheit, protected from light. <p>New Quick SIG Pick available:</p> <ul style="list-style-type: none"> • 0 mg/kg intravenously once; Administer over approximately 30 minutes once every 21 days (Q21D). ABBV-399 must be refrigerated at 2 to 8 degrees C/36 to 46 degree Fahrenheit, protected from light.
BT8009 invest IV	<p>New Form available:</p> <ul style="list-style-type: none"> • 12 mg
Cisplatin IV	<p>New Dose Unit available:</p> <ul style="list-style-type: none"> • mg
DSP-5336 invest Oral	<p>New Alias/Synonym available:</p> <ul style="list-style-type: none"> • Enzomenib invest <p>New Form available:</p> <ul style="list-style-type: none"> • 100 mg tablet

ensartinib Oral	<p>New Dose and Unit available:</p> <ul style="list-style-type: none"> • 25 mg • 100 mg <p>New Maximum Single Dose available:</p> <ul style="list-style-type: none"> • 225 mg <p>New Instructions available:</p> <ul style="list-style-type: none"> • Take 225 mg (two 100 mg capsules and one 25 mg capsule) daily.
Florbetaben f-18 IV	<p>Florbetaben f-18 IV is inactive. New Medication available:</p> <ul style="list-style-type: none"> • florbetaben F-18 IV • Neuraceq (florbetaben F-18 IV)
Florbetapir f-18 IV	<p>Florbetapir f-18 IV is inactive. New Medication available:</p> <ul style="list-style-type: none"> • florbetapir F-18 IV • Amyvid (florbetapir F-18 IV)
Fluorodeoxyglucose f-18 IV	<p>New Form available:</p> <ul style="list-style-type: none"> • 500 mCi/mL 50 mL v1 solution
Gallium 68Ga Gozetotide or 68Ga Ga-PSMA-11 invest IV	<p>Update Medication Name to:</p> <ul style="list-style-type: none"> • AAA517 (Gallium 68Ga Gozetotide or 68Ga Ga-PSMA-11) invest IV
HER3-DXd invest IV	<p>Update Form from 100 mg recon soln (20 mg/mL when prepared) to:</p> <ul style="list-style-type: none"> • 100 mg recon soln <p>Update Instructions:</p> <ul style="list-style-type: none"> • MK-1022 is NOT compatible with 0.9% sodium chloride solution (normal saline).

<p>linvoseltamab-gcpt IV</p>	<p>New default SIG available:</p> <ul style="list-style-type: none"> • 5 mg intravenously once <p>New Maximum Single Dose available:</p> <ul style="list-style-type: none"> • 200 mg <p>New Instructions available:</p> <ul style="list-style-type: none"> • Use Linvoseltamab-gcpt (Lynozytic) Q7D fb Q14D fb Q28D Maintenance regimen to order this medication. Ordering this medication outside of a regimen is not recommended. See Prescribing Information for details on preparation, administration, dose delays, and toxicity management. Linvoseltamab-gcpt is only available through a restricted distribution program, Lynozytic REMS.
<p>LOXO-305 invest Oral Pirtobrutinib invest (LOXO-305 invest Oral)</p>	<p>New Form available:</p> <ul style="list-style-type: none"> • 30 mg tablet <p>New Quick SIG Pick available:</p> <ul style="list-style-type: none"> • 30 mg orally daily • 60 mg orally daily • 120 mg orally daily <p>New default SIG available:</p> <ul style="list-style-type: none"> • 0 mg orally daily; quantity sufficient for 30 days
<p>MK-4280 invest IV</p>	<p>New Quick SIG Pick available:</p> <ul style="list-style-type: none"> • 800 mg intravenously once
<p>RMC-6236 invest Oral</p>	<p>New SIGs available:</p> <ul style="list-style-type: none"> • 140 mg orally daily • 200 mg orally daily <p>New Alias/Synonym available:</p> <ul style="list-style-type: none"> • Daraxonrasib invest
<p>RMC-9805 invest Oral</p>	<p>New Alias/Synonym available:</p> <ul style="list-style-type: none"> • Zoldonrasib invest
<p>SGN-B6A invest IV</p>	<p>New Alias/Synonym available:</p> <ul style="list-style-type: none"> • Sigvotatug vedotin invest

Taletrectinib Oral	<p>New Maximum Single Dose available:</p> <ul style="list-style-type: none">• 600 mg <p>New Instructions available:</p> <ul style="list-style-type: none">• Take on an empty stomach at least 2 hours before or 2 hours after food. <p>Removed Instructions:</p> <ul style="list-style-type: none">• administer on an empty stomach, at least 2 hours before or 2 hours after food/meal(s).
TORL-2-307-ADC invest IV	<p>Update Form from 40 mg solution to:</p> <ul style="list-style-type: none">• 40 mg frozen soln <p>New Form available:</p> <ul style="list-style-type: none">• 60 mg recon soln

Regimen Library

Additions

Regimen Name	Diagnosis
Abiraterone + Prednisone + Degarelix Q28D	Prostate Cancer
Apalutamide + Degarelix Q28D	Prostate Cancer
Cladribine C1D1-5 (C2D1-3) + Cytarabine SQ D1-10 + Venetoclax Q28D	Leukemia, Acute Myeloid (AML)
Darolutamide + Degarelix Q28D	Prostate Cancer
Degarelix + Enzalutamide Q28D	Prostate Cancer
Docetaxel + Abiraterone + Prednisone + ADT Q28D (Abiraterone + Prednisone + Degarelix only)	Prostate Cancer
Docetaxel + Apalutamide + ADT Q28D (Apalutamide + Degarelix only)	Prostate Cancer
Docetaxel + Darolutamide + ADT Q28D (Darolutamide + Degarelix only)	Prostate Cancer
Docetaxel + Enzalutamide + ADT Q28D (Enzalutamide + Degarelix only)	Prostate Cancer
Ensartinib Q30D	Lung Cancer, Non-small Cell (NSCLC)
Fluorouracil (Bolus + CIV) D1-2,15-16,29-30 + Leucovorin + Oxaliplatin (FOLFOX 6, Modified) + Atezolizumab SQ D1,22 Q42D fb Atezolizumab SQ Maintenance D1,22 Q42D	Colon Cancer
Fluorouracil (Bolus + CIV) D1-2 + Leucovorin + Oxaliplatin (FOLFOX 6, Modified) + Atezolizumab IV Q14D fb Atezolizumab IV Maintenance Q14D	Colon Cancer
Gemcitabine D1,8 + Docetaxel D8 (Osteosarcoma)	Sarcoma, Bone (Parent)
Linvoseltamab-gcpt (Lynozytic) Q7D fb Q14D fb Q28D Maintenance	Multiple Myeloma (MM)

Updates

Regimens for the following diagnoses have been updated based on the Collaborative Care Committee voting. Changes include but are not limited to reference update, drug infusion instruction updates, renaming of regimens, premedication template updates and number of cycles.

- Adrenocortical Cancer
- All Problems
- Amyloidosis
- Anal Cancer (Parent)
- Bile Duct Cancer (Parent)
- Bladder Cancer
- Cervical Cancer
- Esophageal Cancer (Parent)
- Fallopian Tube Cancer
- Gallbladder Cancer
- Gastric Cancer
- Head and Neck Cancer (Parent)
- Lung Cancer, Non-small Cell (NSCLC)
- Lung Cancer, Small Cell (SCLC)
- Lymphoma, Non-Hodgkin (NHL) (Parent)
- Melanoma, Uvea, Ciliary Body/Choroid
- Melanoma, Uvea, Iris
- Merkel Cell Carcinoma
- Multiple Myeloma (MM)
- Neuroendocrine Tumor, Carcinoid (Parent)
- Ovarian and Primary Peritoneal Cancer
- Pancreatic Cancer
- Prostate Cancer
- Renal Pelvis and Ureter Cancer
- Sarcoma, Soft Tissue (Parent)
- Testicular Cancer (Parent)
- Thymoma, Malignant
- Urethral Cancer
- Uterine Cancer (Parent)

Renames

Previous Name	New Name
Atezolizumab IV + Bevacizumab + Paclitaxel + Carboplatin Q21D (Part 1 of 2: Induction)	Atezolizumab IV + Bevacizumab + Paclitaxel + Carboplatin Q21D (NSCLC)
Atezolizumab SQ + Bevacizumab + Paclitaxel + Carboplatin Q21D (Part 1 of 2: Induction)	Atezolizumab SQ + Bevacizumab + Paclitaxel + Carboplatin Q21D (NSCLC)
Denosumab (Xgeva) D1,8,15 fb D1 Q28D (Giant Cell Tumor)	Denosumab (120 mg) Q28D (Bone Metastasis)
Daratumumab IV Q28D (Post-Transplant Maintenance)	Daratumumab IV Q28D (Maintenance)
Daratumumab SQ Q28D (Post-Transplant Maintenance)	Daratumumab SQ Q28D (Maintenance)
Denosumab (Xgeva) Q28D (Bone Metastasis)	Denosumab (120 mg) Q28D (Bone Metastasis)
Docetaxel + Darolutamide + ADT Q21D (Docetaxel only)	Docetaxel + Antiandrogen + ADT Q21D (Docetaxel only)
Gemcitabine D1,8 + Docetaxel D8 Q21D	Gemcitabine D1,8 + Docetaxel D8 Q21D (Uterine Sarcoma, Soft Tissue Sarcoma)

Billing & HCPCS Codes

Updates

Medication	HCPCS Codes
Avgemsi (Gemcitabine IV)	J9999 per 1 mg
Bupivacaine-Meloxicam Instillation ER Solution 200 mg-6 mg/7 mL	J3490 per 7 mL
Bupivacaine-Meloxicam Instillation ER Solution 400 mg-12 mg/14 mL	J3490 per 14 mL
Carboprost IM	J3490 per 250 mcg
Clesrovimab-cfor IM	90382 per: <ul style="list-style-type: none"> • 0.7 mL • 105 mg

Denosumab-bbdz Subcutaneous (120 mg/1.7 mL - Wyost)	Q5136 per 1 mg
Esomeprazole IV	J3490 per 20 mg
Florbetaben F-18 IV	Q9983 per: <ul style="list-style-type: none"> • 8.1 mCi • 300 MBq
Florbetapir F-18 IV	A9586 per: <ul style="list-style-type: none"> • 10 mCi • 370 MBq
Fluorescein IV 10 %	J3490 per 500 mg
Fluorescein IV 25 %	J3490 per 500 mg
Influenza Virus Vaccine IM Tri-Split (6 months & older)	90658 per 0.5 mL
Influenza virus vaccine (PF) IM Tri-Split 9 yrs & older (Recombinant)	90673 per 0.5 mL
Isoniazid IM	J3490 per 100 mg
Tesamorelin Subcutaneous (Egrifta WR)	J3590 per 11.6 mg

NDC – HCPCS Crosswalk Additions

Medication (Brand)	HCPCS Codes	NDC
Avgemsi (Gemcitabine IV)	J9999 per 1 mg	<ul style="list-style-type: none"> • 83831012301 • 83831012401